Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-31
2005-05-31
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C424S093210, C536S023500, C536S024100
Reexamination Certificate
active
06900185
ABSTRACT:
The present invention is directed to methods for inhibiting tumor cell growth, causing tumor regression or eliminating tumor cells in a mammal afflicted with a tumor by administering to a TRAIL-sensitive cell a vector having a DNA expression cassette containing a promoter and a DNA sequence encoding TRAIL, wherein the expression of TRAIL results in tumor inhibition, regression or elimination.
REFERENCES:
patent: 5601818 (1997-02-01), Freeman et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5763416 (1998-06-01), Bonadio et al.
patent: 5972899 (1999-10-01), Zychlinsky et al.
patent: 5994298 (1999-11-01), Tsai et al.
patent: 6030945 (2000-02-01), Ashkenazi
patent: 97/01633 (1997-01-01), None
patent: 99/12963 (1999-03-01), None
Wiley et al., Dec. 1995. Immunity, vol. 3, p. 673-682.*
Bonavida et.al.; Selectively of TRAIL-mediated apoptosos of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics, 1999, International Journal of Oncology 15: 793-802.*
Hu et.al.; Development of an Adenovirus Vector with Tetracycline-regulatable Human Tumor Necrosis Factor Gene Expression. 1997. Cancer Research 57 3339-3343.*
2833-2840.*
Pitti et.al.; Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family, 1996, JBC, vol. 271: 12687-12690.*
Kaye et.al.; A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, 1990, Proc. Natl. Acad. sci. vol. 87: 6922-6926.*
Rudinger; Characteristics of the amino acids as components of a peptide hormone sequence, 1976, Peptide Hormones. 1-7.*
Verma et.al.; Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389: 239-242.*
Eck et.al.; Gene-Based Therapy. 1996. Pharmacological Basis of Therapeutics: 77-101.*
Navarro et al., Gene Therapy for Cancer, 1999, Europan Journal of Cancer, vol. 35, No. 6, pp. 867-885.*
Arai et al., Gene transfer of Fas ligand induces tumor regression in vivo, Dec. 1997, Proc. Natl. Acad. Sci., vol. 94, pp. 13862-13867.*
Walczak et al Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Feb. 1999, Nature.*
Gliniak et al., Tumor Necrosis Factor-related Apoptosis-inducing Ligand's Antiumor Activity in Vivo is Enhanced by the Chemotherapeutic Agent CPT-11, Dec. 15, 1999, Cancer Research, vol. 59, pp. 6153-6158.*
Chinnaiyan, A.M., et al., “Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy”,PNAS, 97(4), pp. 1754-1759, (Feb. 15, 2000).
Griffith, T.S., et al., “Adenoviral-mediated gene tranfer of TRAIL induces tumor cell apoptosis”,FASEB J., 14(6), p. A1003, (May 12-16, 2000).
Griffith, T.S., et al., “Adenoviral-Mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis”,J. of immunology, 165, pp. 2886-2894, (Sep. 2000).
Putzer, B.M., et al., “Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer”,Human Gene Therapy, 9(5), pp. 707-718, (Mar. 20, 1998).
Roth, W., et al., “Death ligands/death receptors, new weapons against malignant glioma”,Neuroforum, vol. 5(3), pp. 87-92, (1999).
Son, K., “Cisplatin-based tumor necrosis factor-related apoptosis-inducing ligand (trail) gene therapy of human breast carcinoma resistant to drugs or hormone”,Breast Cancer Research and Treatment, 57(1), p. 54, (Dec. 8-11, 1999).
Alderson, M.R., et al., “Fas Ligand Mediates Activation-induced Cell Death in Human T Lymphocytes”,J. Exp. Med., 181, pp. 71-77, (Jan. 1995).
Armitage, R.J., “Tumor necrosis factor receptor superfamily members and their ligands”,Current Opinion in Immunology, 6, pp. 407-413, (1994).
Ashkenazi, A., et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand”,The Journal of Clinical Investigation, 104(2), pp. 155-162, (Jul. 1999).
Bergelson, J.M., et al., “Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5”,Science, 275, pp. 1320-1323, (Feb. 1997).
Cerami, A., et al., “The role of cachectin/TNF in endotoxic shock and cachexia”,Immunology Today, 9(1), pp. 28-31, (1988).
Cosman, D., “A Family of Ligands for te TNF Receptor Superfamily”,Stem Cells, 12, pp. 440-455, (1994).
Degli-Esposti, M.A., et al., “Cloning and Characterization of Trail-R3, a Novel Member of the Emerging Trail Receptor Family”,J. Exp. Med., 186(7), pp. 1165-1170, (Oct. 1997).
Degli-Esposti, M.A., et al., “The Novel Receptor TRAIL-R4 Induces NF-kB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain”,Immunity, 7, pp. 813-820, (Dec. 1997).
Griffith, T.S., et al., “Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege”,Science, 270, pp. 1189-1192, (Nov. 1995).
Griffith, T.S., et al., “Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus”,Moelcular Therapy, vol. 4, No. 3, 1-10, (Sep. 2001).
Griffith, T.S., et al., “TRAIL: a molecular with multiple receptors and control mechanisms”,Current Opinion in Immunology, 10(5), pp. 559-563, (Oct. 1998).
Hahne, M., et al., “Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape”,Science, 274, pp. 1363-1366, (Nov. 1996).
Landis, S.H., et al., “Cancer Statistice, 1999”,CA—Cancer Journal for Clinicians, 49(1), pp. 8-31, (Jan./Feb. 1999).
MacFarlane, M., et al., “Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL”,The Journal of Biological Chemistry, 272(41), pp. 25417-25420, (Oct. 1997).
Marsters, S.A., et al., “A novel receptor for Apo2L/TRAIL contains a truncated death domain”,Current Biology, 7, pp. 1003-1006, (1997).
Ogasawara, J., et al., “Lethal effect of the anti-Fas antibody in mice”,Nature, 364, pp. 806-809, (Aug. 1993).
Pan, G., et al., “An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL”,Science, 277, pp. 815-818, (Aug. 1997).
Pan, G., et al., “The Receptor for the Cytotoxic Ligand TRAIL”,Science, 276, pp. 111-113, (Apr. 1997).
Pan, G., et al., “Trundd, a new member of the TRAIl receptor family that antagonizes TRAIL signalling”,FEBS Letters, 424, pp. 41-45, (1998).
Pitti, R.M., et al., “Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family”,The Journal of Biological Chemistry, 271(22), pp. 12687-12690, (May 1996).
Schneider, P., et al., “Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity”,J. Exp. Med., 187(8), pp. 1205-1213, (Apr. 1998).
Schulze-Osthoff, K., et al., “Apoptosis signaling by death receptors”,Eur. J. Biochem., 254, pp. 439-459, (1998).
Sheridan, J.P., et al., “Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors”,Science, 277, pp. 818-821, (Aug. 1997).
Siemens, D.R., et al., “Biomarker distribution after injection into the canine prostate: implications for gene therapy”,BJU International, vol. 86, No. 9, 1076-1083, (Dec. 2000).
Siemens, D.R., et al., “Cutting edge: Restoration of the ability to generate CTL in mice immune in adenovirus by delivery of virus in a collagen-based matrix”,The Journal of Immunology, vol. 166, No. 2, 731-735, (Jan. 15, 2001).
Siemens, D.R., et al., “Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model”,J. National Cancer Inst., vol. 92, No. 5, 403-412, (Mar. 1, 2000).
Song, K., et al., “Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Is an Inhibitor of Autoimmune Inflammation and Cell
Griffith Thomas S.
Ratliff Timothy
Chen Shin-Lin
Fish & Richardson P.C. P.A.
University of Iowa Research Foundation
LandOfFree
Method of inducing tumor cell apoptosis using trail/Apo-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inducing tumor cell apoptosis using trail/Apo-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inducing tumor cell apoptosis using trail/Apo-2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3458622